CAR T cells for CD4-positive AML before stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immunotherapy (CAR T cells) designed to target and kill leukemia cells that have a specific marker (CD4). The goal is to help people with acute myeloid leukemia (AML) that has not responded to standard treatments get ready for a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old.
- Your AML must be CD4-positive (a protein on the surface of the cancer cells).
- You must have tried at least one standard treatment that did not work.
- Your kidneys, liver, and heart need to be working well enough (doctors will check this).
- You must have a potential donor for a stem cell transplant after this treatment.
- You cannot be pregnant or have an uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This Phase 1 study tests a type of lab-made immune cell therapy (CAR T cells) made from your T cells to treat AML that has relapsed or not responded, as long as the cancer shows a marker called CD33. The goal is to see if the treatment is safe and can help control AML after it returns or resists standard therapy.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD4 on CMML cells. It is for people whose CMML has come back or not responded to standard treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.